Evidence of SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2 mRNA Vaccine
SARS-CoV-2 mRNA vaccines have demonstrated high efficacy and immunogenicity, but limited information is currently available on memory B cell generation and long-term persistence. Here, we investigated spike-specific memory B cells and humoral responses in 145 subjects, up to 6 months after the BNT16...
Main Authors: | Annalisa Ciabattini, Gabiria Pastore, Fabio Fiorino, Jacopo Polvere, Simone Lucchesi, Elena Pettini, Stefano Auddino, Ilaria Rancan, Miriam Durante, Michele Miscia, Barbara Rossetti, Massimiliano Fabbiani, Francesca Montagnani, Donata Medaglini |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-09-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.740708/full |
Similar Items
-
Trajectory of Spike-Specific B Cells Elicited by Two Doses of BNT162b2 mRNA Vaccine
by: Annalisa Ciabattini, et al.
Published: (2023-06-01) -
Keratoplasty rejection after messenger RNA vaccine (BNT162b2) for COVID-19
by: Maria Eduarda Andrade e Andrade, et al.
Published: (2022-01-01) -
Spike-Specific Memory B Cell Response in Hematopoietic Cell Transplantation Recipients following Multiple mRNA-1273 Vaccinations: A Longitudinal Observational Study
by: Elena Pettini, et al.
Published: (2024-03-01) -
Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 Omicron variant
by: Gabiria Pastore, et al.
Published: (2024-12-01) -
Toxicological Assessments of a Pandemic COVID-19 Vaccine—Demonstrating the Suitability of a Platform Approach for mRNA Vaccines
by: Cynthia M. Rohde, et al.
Published: (2023-02-01)